These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29755982)

  • 1. Clinical Genetics in Interstitial Lung Disease.
    Newton CA; Molyneaux PL; Oldham JM
    Front Med (Lausanne); 2018; 5():116. PubMed ID: 29755982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures.
    Furusawa H; Cardwell JH; Okamoto T; Walts AD; Konigsberg IR; Kurche JS; Bang TJ; Schwarz MI; Brown KK; Kropski JA; Rojas M; Cool CD; Lee JS; Wolters PJ; Yang IV; Schwartz DA
    Am J Respir Crit Care Med; 2020 Nov; 202(10):1430-1444. PubMed ID: 32602730
    [No Abstract]   [Full Text] [Related]  

  • 3. Pathology of Chronic Hypersensitivity Pneumonitis What Is It? What Are the Diagnostic Criteria? Why Do We Care?
    Churg A; Bilawich A; Wright JL
    Arch Pathol Lab Med; 2018 Jan; 142(1):109-119. PubMed ID: 28537805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic analysis of sixteen autopsy cases of chronic hypersensitivity pneumonitis and comparison with idiopathic pulmonary fibrosis/usual interstitial pneumonia.
    Akashi T; Takemura T; Ando N; Eishi Y; Kitagawa M; Takizawa T; Koike M; Ohtani Y; Miyazaki Y; Inase N; Yoshizawa Y
    Am J Clin Pathol; 2009 Mar; 131(3):405-15. PubMed ID: 19228646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.
    Adegunsoye A; Vij R; Noth I
    Chest; 2019 May; 155(5):1026-1040. PubMed ID: 30660786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility.
    Cameli P; Caffarelli C; Refini RM; Bergantini L; d'Alessandro M; Armati M; Tomai Pitinca MD; Sestini P; Gonnelli S; Bargagli E
    Front Med (Lausanne); 2020; 7():568020. PubMed ID: 33195314
    [No Abstract]   [Full Text] [Related]  

  • 8. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis.
    Jacob J; Bartholmai BJ; Egashira R; Brun AL; Rajagopalan S; Karwoski R; Kokosi M; Hansell DM; Wells AU
    BMC Pulm Med; 2017 May; 17(1):81. PubMed ID: 28472939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
    Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
    Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.
    Bowman WS; Echt GA; Oldham JM
    Front Med (Lausanne); 2021; 8():680997. PubMed ID: 34041256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis.
    Invernizzi R; Wu BG; Barnett J; Ghai P; Kingston S; Hewitt RJ; Feary J; Li Y; Chua F; Wu Z; Wells AU; George PM; Renzoni EA; Nicholson AG; Rice A; Devaraj A; Segal LN; Byrne AJ; Maher TM; Lloyd CM; Molyneaux PL
    Am J Respir Crit Care Med; 2021 Feb; 203(3):339-347. PubMed ID: 32692582
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenetics and interstitial lung disease.
    Oldham JM; Noth I; Martinez FJ
    Curr Opin Pulm Med; 2016 Sep; 22(5):456-65. PubMed ID: 27253772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bleomycin Model of Pulmonary Fibrosis.
    Liu T; De Los Santos FG; Phan SH
    Methods Mol Biol; 2017; 1627():27-42. PubMed ID: 28836192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Chronic Hypersensitivity Pneumonitis Biomarkers with Machine Learning and Differential Co-expression Analysis.
    Zhang H; Wang S; Huang T
    Curr Gene Ther; 2021; 21(4):299-303. PubMed ID: 33292121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cohort study of interstitial lung diseases in central Denmark.
    Hyldgaard C; Hilberg O; Muller A; Bendstrup E
    Respir Med; 2014 May; 108(5):793-9. PubMed ID: 24636811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of new diagnostic criteria for chronic hypersensitivity pneumonitis established on the basis of a Delphi survey: A Japanese cohort study.
    Takei R; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Johkoh T; Tabata K; Fukuoka J; Kondoh Y
    Respir Investig; 2020 Jan; 58(1):52-58. PubMed ID: 31718936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis.
    De Sadeleer LJ; Verleden SE; De Dycker E; Yserbyt J; Verschakelen JA; Verbeken EK; Nemery B; Verleden GM; Hermans F; Vanaudenaerde BM; Wuyts WA
    Respirology; 2018 Dec; 23(12):1160-1165. PubMed ID: 29897160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.
    Meyer KC
    Expert Rev Respir Med; 2017 May; 11(5):343-359. PubMed ID: 28345383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
    Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
    Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.